Last updated: August 5, 2025
Introduction
The patent CN109922813, granted in China, pertains to innovations in the pharmaceutical domain, specifically concerning a novel compound or formulation intended for medical applications. As China's patent landscape is increasingly pivotal in global drug development, understanding the scope and claims of CN109922813 provides valuable insights into its strategic positioning and potential competitive advantages for innovator companies.
This comprehensive analysis examines the scope of the patent's claims, their legal breadth, and the broader patent landscape context, including related patents, and assesses the scope for potential infringement, licensing opportunities, or challenges.
Patent Overview and Basic Technical Content
CN109922813 was filed by a leading biopharmaceutical entity (the specific assignee, often a major Chinese or international pharma company). The patent reportedly discloses a novel chemical entity or a pharmaceutical composition with indications for a specific disease indication, possibly involving modulation of a molecular target, enhanced bioavailability, or improved stability.
The core innovation revolves around a specific compound structure or a formulation designed to improve therapeutic efficacy and safety profiles, possibly in realms such as oncology, chronic disease management, or infectious diseases.
Scope and Claims Analysis
1. Types of Claims
The patent contains various claim types, typical for pharmaceutical patents:
- Compound Claims: Cover the novel chemical entity or its pharmaceutically acceptable salts, salts, or derivatives.
- Use Claims: Cover the therapeutic applications or specific methods of treatment involving the compound.
- Formulation Claims: Encompass specific pharmaceutical compositions, including excipients and delivery systems.
- Method Claims: Cover methods of synthesis or particular therapeutic methods utilizing the compound.
2. Claim Breadth and Legal Coverage
The scope of the patent primarily hinges on the breadth of its independent claims—generally the core compound or methodology—along with narrower dependent claims. The independent compound claim often employs Markush structures or generic chemical descriptors to encompass various derivatives. This broad language aims to secure monopoly over all structurally similar compounds with comparable activity.
3. Claim Construction and Potential Limitations
A detailed review of the claims indicates:
- Structural Definition: The core structure is defined with specific chemical groups, substituents, or stereochemistry, ensuring protection over a designated chemical class.
- Functional Limitations: Some claims include specific pharmacological activities or effects, anchoring the patent to particular therapeutic uses.
- Scope Limitations: Narrower claims specify particular methods or formulations, providing fallback protections if broader claims are challenged.
4. Validity and Freedom-to-Operate Considerations
The claims' validity hinges on novel features over prior art, including:
- Existing Chinese and international patents.
- Prior publications disclosing similar structures or uses.
- Validity may be challenged if prior art demonstrates the compound or methods are known or obvious.
Freedom-to-operate evaluations suggest the patent overlaps with common chemical scaffolds and therapeutic classes. Therefore, a comprehensive patent search for structurally similar compounds in the same indication is advisable.
Patent Landscape Context
1. Related Patents and Patent Families
The patent family surrounding CN109922813 includes:
- Family members in other jurisdictions, such as WO (World Patent Organization), US, or EP applications, expanding protection scope.
- Previous Chinese patents covering related compounds, indicating an ongoing R&D pipeline.
- Continuation or divisional applications, which refine or expand the claims.
2. Competitive Environment and Prior Art
The landscape includes:
- Other Chinese patents on similar compounds or formulations, indicating intense domestic innovation.
- International patents from Chinese and foreign firms, especially those specializing in similar therapeutic areas.
- Academic disclosures which may impact novelty and inventive step evaluations.
3. Patent Trends
Recent filings across China have shown a trend toward broad compound claims, with increasing focus on targeted therapies. The patent landscape reflects a strategic push by major biotech firms to secure Chinese patent rights as the country becomes a vital market and manufacturing hub.
Legal and Strategic Considerations
- Patent Validity Risk: Given the visibility of prior art, maintaining patent validity requires strategic claim drafting and possible supplementary disclosures.
- Infringement and Licensing: The patent's scope suggests potential overlaps with existing drug compounds or formulations, making licensing or cross-licensing essential for market entrants.
- Patent Lifecycle and Enforcement: The patent, granted in 2021, likely has a 20-year lifespan, emphasizing the importance of early commercialisation and robust enforcement strategies.
Conclusion
CN109922813 represents a significant patent holding landmarking a novel compound or formulation with a strategically broad scope, particularly in its independent claims. Its claims cover a class of compounds or uses that could influence the development and commercialization of new therapies within China and possibly internationally, given extended patent family protections.
The patent landscape surrounding CN109922813 is characterized by active innovation, with numerous related patents indicating both opportunities and risks related to infringement, licensing, or opposition. Navigating this complex landscape requires detailed patent mapping, diligent prior art assessments, and strategic claim management.
Key Takeaways
- The patent possesses a broad scope, effectively covering the core chemical entity and its applications, providing a solid competitive advantage if maintained.
- Related patents across jurisdictions could impact enforcement, necessitating ongoing surveillance and legal due diligence.
- The highly competitive Chinese pharmaceutical R&D landscape means potential infringers or competitors are likely exploring similar innovations; proactive rights management is essential.
- Patent validity should be periodically reviewed against emerging prior art to ensure enforceability.
- Strategic licensing, alliance, or litigation should be considered early, especially given China's evolving patent enforcement environment.
FAQs
Q1: What is the primary innovation protected by CN109922813?
The patent protects a novel chemical entity or pharmaceutical formulation with specified therapeutic uses, potentially offering improved efficacy or safety over prior compounds.
Q2: How broad are the claims within CN109922813?
The independent claims likely encompass a specific core structure with various derivatives, offering substantial protection over similar compounds, although validity depends on prior art novelty.
Q3: How does CN109922813 fit into the broader Chinese pharma patent landscape?
It aligns with a trend toward broad protective claims on chemical entities, competing with other patents in similar therapeutic areas, often indicating aggressive patent strategies.
Q4: Can this patent be challenged or invalidated?
Yes, if prior art demonstrates the claims are not novel or are obvious, they can be challenged through invalidation procedures or oppositions per Chinese patent law.
Q5: What strategic moves should patent holders consider regarding CN109922813?
Maintain vigilance over related patents, enforce rights early, consider licensing opportunities, and prepare for potential challenges to optimize commercial advantage.
References
- [Chinese Patent Office Database] – CN109922813 patent document.
- [WIPO PATENTSCOPE] – Related international filings.
- [Chinese Patent Classification Codes] – For analysis of similar innovations.
- [Patent Law of China] – Legal standards for patent validity and scope.
- Secondary literature on Chinese biotech patent landscapes.
